FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPRO	VAL
OMB	3235-
Number:	0104
Estimated average	ge
burden hours pei	٢
response	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting Person *-	ate of Event Requiring			3. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]							
POSNER BRIAN M	/Day/Year)		Dissistances, mer [chich]							
(Last) (First) (Middl C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE	04/01/	-04/01/2018			erson(s) to I	Issue all	of Reporting uer l applicable)10% OwnerOther (specify		5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) MADISON, WI 53716					le below) Chief Fi		below) cial Office	r	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person		
(City) (State) (Zip))	Tal	ble I	- Non	-Derivati	ive :	Securitie	s Ben	eficially	Owned	
1.Title of Security (Instr. 4)		2. Amount of Beneficially ((Instr. 4)						Owner			
Reminder: Report on a separate line	e for each class	s of securit	ies bei	neficia	lly owned d	lirec	tly or indir	ectly.		SEC 1473 (7-02)	
Persons who not required number.	o respond to	the colle	ection	n of in	formation	ı co	ntained i	n this		e	
Table II - Derivative S	ecurities Ben	eficially O	wned	(e.g.,]	puts, calls,	war	rants, opti	ions, co	nvertibl	e securities)	
1. Title of Derivative Security (Instr. 4)	2. Date Exerc	te Exercisable S Expiration Date S (/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conversion or Exercise Price of	5. n Own	nership n of ivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	e _{Title} An		unt or Numbares	ber	Derivative Security	Dire or In (I)	urity: ect (D) ndirect tr. 5)		
Reporting Owners											
Reporting Owner Name / Address		Relationships									
	Director	Director 10% Owner Officer C						her			
POSNER BRIAN M C/O CELLECTAR BIOSCIEN	NCES, INC.				Cl.:-CD		-:-1 Occ				

Chief Financial Officer

Signatures

MADISON, WI 53716

3301 AGRICULTURE DRIVE

/s/ Christine Blakely, Attorney-in-fact for Brian M. Posner	04/05/2018
**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

No securities are beneficially owned. Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Stacy Fredericks and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Stacy Fredericks and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Stacy Fredericks and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: April 4, 2018 Signed:/s/ Brian M. Posner

Print Name: Brian M. Posner